MorningSignal
Research Platform
2026-09-28 13:40
type: earnings-brief session: AM date: 2026-08-03 daily_note: "[[Daily/2026-08-03]]" status: PROVISIONAL - RELEASE ONLY market_data_as_of: 2026-07-31 tags: [earnings, sellside]
← [[Daily/2026-08-03|Back to the daily note]]
Historical catch-up discipline. This report reconstructs the 8:00 a.m. ET target-date decision set. Security prices and broad-market context are the Friday, 2026-07-31 close, the latest completed U.S. session available to the Monday-morning workflow. It does not use the later 2026-08-03 close or any 2026-08-04 tape. All Tier 1/2 conclusions are PROVISIONAL — RELEASE ONLY because the relevant live calls had not finished by the cutoff or the issuer did not offer public Q&A.
| Ticker | Release verified | Market cap | 2026-07-31 close | Prior TIF thesis / Ledger | Call state at 08:00 ET | Tier | Status / reason |
|---|---|---|---|---|---|---|---|
| [[MAR]] | 07:00 ET SEC/IR | $98.3B | $372.83 | None located | 08:30 call pending | Tier 1 | PROVISIONAL — RELEASE ONLY; material global lodging read-through |
| [[TSN]] | 07:37 ET SEC | $20.4B | $57.96 | None located | call pending | Tier 1 | PROVISIONAL — RELEASE ONLY; guide cut and protein-cycle split |
| [[CNH]] | 06:35 ET SEC | $12.7B | $10.25 | None located | 09:00 call pending | Tier 1 | PROVISIONAL — RELEASE ONLY; agriculture-cycle and dealer-credit read-through |
| [[KRYS]] | 07:04 ET SEC | $10.1B | $341.12 | None located | 08:30 call pending | Tier 1 | PROVISIONAL — RELEASE ONLY; commercial gene-therapy and pipeline timing |
| [[CNA]] | 06:10 ET SEC/IR | $14.2B | $52.47 | None located | no public Q&A; prepared remarks only | Tier 2 | PROVISIONAL — RELEASE ONLY |
| [[MUFG]] | 06:02 ET SEC | $266.4B | $22.45 | None located | no investor meeting listed | Tier 2 | PROVISIONAL — RELEASE ONLY |
| [[L]] | 06:06 ET SEC/IR | $23.9B | $116.01 | None located | prepared remarks only | Tier 3 | DEFERRED to 2026-08-04; CNA overlap and missing dated SOTP hurdle |
PM decision line — WAIT, moderate confidence, PROVISIONAL — RELEASE ONLY. The prior company hurdle was Q2 worldwide RevPAR growth of 1.5–2.5%, adjusted EBITDA of $1.525–1.550 billion and adjusted EPS of $2.99–3.06; Nasdaq’s dated calendar showed $3.06 EPS. Marriott delivered 3.4% RevPAR, $1.592 billion EBITDA and $3.19 adjusted EPS, then raised FY RevPAR and EPS. The business delta is positive, but at $372.83 the security already discounts about 31.8x the new FY EPS midpoint, so the actionable entry is $335 or lower, conditional on the call validating recurring co-brand economics.
| Metric | Prior guide / dated Street | Actual | Variance and rate of change | Classification |
|---|---|---|---|---|
| Worldwide RevPAR | +1.5% to +2.5% | +3.4% YoY | +140 bps vs midpoint; Q1 was +4.2%, so growth decelerated 80 bps sequentially | STRUCTURAL POSITIVE, with slowing second derivative |
| U.S. & Canada RevPAR | not separately guided | +5.0% | broad-based across chain scales/segments | STRUCTURAL POSITIVE |
| International RevPAR | not separately guided | -0.5% | EMEA below -5%; Middle East -43%, offsetting APEC >+5% and Greater China >+3% | GEOPOLITICAL / MIX NEGATIVE |
| Adjusted EBITDA | $1.525–1.550B | $1.592B | +$54.5M, or +3.5%, vs midpoint; +13% YoY | STRUCTURAL POSITIVE |
| Adjusted EPS | guide $2.99–3.06; Nasdaq $3.06 | $3.19 | +$0.165 vs guide midpoint and +$0.13 vs Nasdaq; +20% YoY | STRUCTURAL POSITIVE |
| Net rooms | 4.5–5.0% FY | +4.5% YoY; 17,900 net adds | at low end of FY range; pipeline +7% to 629,000 rooms | POSITIVE, execution still required |
The EPS-quality gate passes directionally: adjusted EPS excludes a $68 million impairment and other defined items, while a $27 million litigation accrual reduced owned/leased contribution by $0.08 per share. The $0.13 beat versus Nasdaq is not a tax/share-count artifact: adjusted EBITDA exceeded the prior midpoint by $54.5 million and fee revenue rose 14%. The litigation and impairment explain GAAP-to-adjusted differences, not the operating beat.
Marriott is asset-light: RevPAR and room count multiply into franchise/base fees, while incentive fees depend on owner-level hotel profit. Three causal KPIs matter. First, RevPAR of +3.4% combines price and occupancy and feeds fee revenue with limited incremental corporate cost. Second, 4.5% net-room growth expands the fee-bearing base even if same-hotel RevPAR slows. Third, the 629,000-room pipeline, 44% under construction, controls the conversion of signed demand into future fee revenue. Franchise and base fees rose 14% to $1.366 billion; this outpaced RevPAR plus rooms because higher co-brand card fees added a second, higher-margin layer.
The compound positive is causal: U.S. RevPAR, net-room growth and co-brand economics all lift fee revenue, which then produced 13% EBITDA growth. The compound negative is also causal: Middle East disruption cut international RevPAR and incentive fees, while higher debt raised quarterly net interest expense $10 million. The buried signal is the card-contract contribution. FY gross-fee guidance moved to $6.025–6.055 billion from $5.925–5.985 billion, roughly an $85 million midpoint increase, while FY EBITDA midpoint rose $70 million. That near-one-for-one conversion suggests the contract uplift is high margin; the call must separate recurring economics from timing or upfront benefits.
FY2026 RevPAR moved from 2–3% to 3–3.5%; EBITDA from $5.880–5.970 billion to $5.965–6.025 billion; adjusted EPS from $11.38–11.63 to $11.64–11.81. Driver algebra is: RevPAR × system rooms + co-brand fees → gross fees; gross fees minus G&A and owned-hotel drag → EBITDA; EBITDA minus higher interest/tax divided by a shrinking share count → EPS. FY1 EPS midpoint rises $0.22. A simple FY2 sensitivity is more honest than false precision: 3% RevPAR plus 4.5% rooms and modest card growth can produce high-single-digit fee growth; at 30x $12.7–13.2 EPS, value is $381–396, while a 27x de-rating gives $343–356. The pre-call bull/base/bear values are $400/$352/$300 with 25%/50%/25% weights, or $351 probability-weighted. The current price is above that provisional value.
| Live claim | Release evidence | Verdict | Next resolution |
|---|---|---|---|
| Asset-light fees can outgrow RevPAR | fee revenue +14% on RevPAR +3.4% and rooms +4.5% | strengthened | quantify card contribution on call |
| Middle East weakness is temporary | regional RevPAR -43%, but other international regions grew | unresolved | booking pace and cancellation data |
| Premium valuation is justified by durable double-digit EPS | EBITDA +13%, FY EPS midpoint +1.9% | strengthened, but mostly priced | FY2 fee/interest bridge |
| Thesis pillar | New evidence | Status |
|---|---|---|
| Demand / volume | U.S. broad-based strength; international mixed | REINFORCED |
| Pricing / mix | ADR strength; regional mix drag | REINFORCED |
| Margin architecture | fee growth converted strongly to EBITDA | IMPROVED |
| Competition | pipeline at record, no contrary evidence | REINFORCED |
| Balance sheet / allocation | debt $16.9B, $1.1B Q2 repurchases | UNCHANGED |
| Management credibility | beat and raised, but call pending | UNRESOLVED |
| Catalyst timing | card economics and Q3 guide now central | IMPROVED |
Entering the print, the story was resilient U.S. travel versus Middle East disruption. After release, the story became fee acceleration from RevPAR, rooms and cards, with the geopolitical drag bounded. After call and settled reaction are PENDING — CALL / NOT OBSERVED AT AM CUTOFF. Business delta: better fee durability. Estimate delta: FY1 EPS up about 2%, FY2 bias positive. Stock delta: valuation absorbs most of it.
Three decisive call questions: How much of the $85 million FY fee-guide midpoint increase is recurring card economics? What booking/cancellation evidence supports normalization after the 43% Middle East decline? How much interest expense and buyback accretion is embedded in the FY EPS range?
Decision card: WAIT; no initial size. Confirm with Q3 RevPAR at least 3.5% and FY EBITDA at least $5.995 billion. Falsify if net-room growth falls below 4.5% or FY EPS is cut below $11.64. Entry trigger: $335 or lower with the recurring card contribution verified. Next proof: 08:30 ET call, then Q3 2026. 10-second PM line: excellent operating beat, but the stock already pays for it.
PM decision line — WAIT, moderate confidence, PROVISIONAL — RELEASE ONLY. Nasdaq’s dated EPS estimate was $1.03; Tyson delivered $0.99 adjusted EPS and flat sales, while Chicken and Prepared Foods masked another Beef loss. The decisive change is not the four-cent miss: total FY adjusted operating-income guidance fell from $2.2–2.4 billion to $2.1–2.3 billion because Beef deteriorated. Wait for $52 or lower and evidence that Beef loss is no worse than the new range.
| Metric | Prior guide / Street | Actual / new guide | Variance and rate of change | Classification |
|---|---|---|---|---|
| Adjusted EPS | Nasdaq $1.03 | $0.99 | -$0.04; +9% YoY | STRUCTURAL MIX NEGATIVE |
| Sales | prior FY +2–4% | $13.868B, flat YoY; +0.6% ex legal accrual | volume -2.8%, price +3.4% | MIXED |
| Adjusted operating income | no public quarterly consensus | $547M, +8% YoY | margin 3.9%; segment strength offset corporate items | STRUCTURAL POSITIVE |
| Beef adjusted OI | FY loss $(500)–$(350)M | Q3 $(138)M; FY $(650)–$(500)M | guide midpoint worsened $150M | STRUCTURAL NEGATIVE |
| Chicken adjusted OI | FY $1.90–2.05B | Q3 $488M; FY unchanged | margin 11.2% vs 10.6% | STRUCTURAL POSITIVE |
| Total adjusted OI | FY $2.2–2.4B | FY $2.1–2.3B | midpoint -$100M, -4.3% | STRUCTURAL NEGATIVE |
The EPS-quality check is cautious. GAAP EPS was $0.52 and adjusted EPS $0.99; the release adds back restructuring, legal contingencies and leadership-transition costs. The $98 million legal accrual reduced Chicken sales but was excluded from adjusted margin. Because adjusted operating income still rose only 8% while adjusted EPS rose 9%, the result is not dominated by tax or buyback. Yet the large GAAP-adjusted gap means the quality of the $0.99 must be judged on cash, not the headline.
Tyson’s economics are a spread business. Beef margin equals boxed-beef realization minus live-cattle cost and plant conversion cost; Chicken margin equals pricing/mix minus feed, labor and plant execution; Prepared Foods adds branded pricing and mix. Beef volume fell 15.9% while price rose 12.1%, and adjusted Beef loss worsened to $138 million from $116 million. Scarce cattle pushed input costs faster than Tyson could recover them. Chicken volume rose 1.0%, price 2.2%, and adjusted margin expanded 60 bps to 11.2%. Prepared Foods volume was flat and price rose 1.6%, but adjusted margin fell 70 bps to 12.6%.
The compound flag is negative: Beef’s volume contraction and higher cattle cost are causally linked, because limited herd supply both reduces throughput and raises unit procurement cost. Chicken strength is not merely coincidental; it diversifies profit while Beef absorbs the cattle trough. The buried signal is guidance asymmetry. Chicken did not need another guide raise to absorb a $150 million deterioration in Beef; instead total-company midpoint fell only $100 million, implying roughly $50 million of offset elsewhere. That is evidence the multi-protein portfolio works, but not proof consolidated earnings have bottomed.
FY adjusted operating-income midpoint falls from $2.3 billion to $2.2 billion. Sales midpoint narrows from +3% to +3%, while FCF midpoint stays $1.5 billion and capex midpoint falls from $0.85 billion to $0.8 billion. The algebra is: protein volume × price minus livestock/feed spread minus plant cost → segment OI; less corporate/amortization and interest/tax → EPS; add D&A, working capital and subtract capex → FCF. FY1 estimates should fall roughly 4–5% at operating income before any tax/share offsets. FY2 turns on cattle availability: if Beef improves $250 million and Chicken holds $1.9 billion-plus, consolidated OI can recover; if Beef remains a $500 million loss, EPS remains range-bound.
At the July 31 market cap of about $20.4 billion, midpoint FCF of $1.5 billion implies a 7.4% equity FCF yield. At $52, the yield would approach 8.2% if FCF holds. That is the margin-of-safety threshold; at $57.96, the stock is not expensive, but the range of Beef outcomes is still too wide.
| Claim | Evidence | Verdict | Next proof |
|---|---|---|---|
| Chicken recovery can carry the portfolio | Q3 margin 11.2%, OI $488M | strengthened | Q4 margin |
| Beef losses are near trough | FY loss range cut to $(650)–$(500)M | weakened | herd/cattle spread |
| Branded Prepared Foods protects margin | sales +1.7%, adjusted margin -70 bps | weakened | price/cost bridge |
| Cash conversion supports downside | FCF guide unchanged at $1.3–1.7B | unresolved | FY cash |
| Pillar | Status | Mechanism |
|---|---|---|
| Demand / volume | WEAKENED | consolidated volume -2.8%, Beef -15.9% |
| Pricing / mix | REINFORCED | +3.4% price, though driven partly by scarcity |
| Margin | UNCHANGED | Chicken offsets Beef; total guide cut |
| Competition | UNRESOLVED | no share detail beyond brands |
| Balance sheet | IMPROVED | debt down $824M, liquidity $4.0B |
| Credibility | WEAKENED | total guide cut after prior reaffirmation |
| Catalyst timing | UNCHANGED | cattle cycle and Q4 remain decisive |
Entering the print, the market needed Chicken strength to offset a manageable Beef trough. After release, Chicken was proven but the trough moved lower. After call and settled reaction are PENDING — CALL. Business delta: portfolio diversification works, but Beef worsened. Estimate delta: FY1 down; FY2 depends on herd supply. Stock delta: valuation is reasonable, yet no release-only edge exists.
Three call questions: What cattle-cost and utilization assumptions produce the new Beef loss range? What portion of Chicken margin is structural plant execution versus favorable feed? Why did Prepared Foods margin contract despite positive price?
Decision card: WAIT; 0% size. Confirm if Chicken FY OI is at least $2.0 billion and Beef loss is no worse than $500 million. Falsify if FCF falls below $1.3 billion or Chicken margin falls below 10%. Entry: $52 or less with the Beef range stabilized. Next catalyst: call and Q4 FY2026. PM line: diversification softened the blow; it did not end the cattle-cycle risk.
PM decision line — WAIT, moderate confidence, PROVISIONAL — RELEASE ONLY. CNH beat Nasdaq’s $0.11 EPS snapshot with $0.13 adjusted EPS and narrowed FY guidance toward the upper half of prior ranges. The release supports better execution at an agriculture trough, but Agriculture margin fell 290 bps, Construction margin fell 280 bps, and 30-day-past-due receivables rose to 4.4%. At $10.25, 23.6x midpoint FY EPS, wait for $8.50 or cleaner dealer-credit evidence.
| Metric | Prior guide / Street | Actual / new guide | Variance | Classification |
|---|---|---|---|---|
| Adjusted EPS | Nasdaq $0.11 | $0.13 | +$0.02; -24% YoY | POSITIVE VS STREET, CYCLICAL NEGATIVE YoY |
| Consolidated revenue | no dated public mean | $4.803B, +2% reported / flat CC | FX aided | NOISE / MIXED |
| Industrial net sales | prior Ag -5% to flat; Construction flat | Q2 +3% reported / +1% CC | Construction delayed shipments helped | TIMING POSITIVE |
| Agriculture margin | FY 4.5–5.5% | Q2 5.2%; FY 5.0–5.5% | range floor +50 bps, but Q2 -290 bps YoY | TROUGH IMPROVEMENT |
| Construction margin | FY 1–2% | Q2 1.7%; FY 1.8–2.3% | range +55 bps midpoint | POSITIVE, low quality until tariff offset proves |
| FCF | $150–350M | $200–400M | midpoint +$50M | STRUCTURAL POSITIVE |
The EPS quality check passes narrowly: adjusted EPS is $0.13 versus $0.11 GAAP, so only $0.02 comes from adjustments. The beat is not tax-driven; the adjusted ETR was 25.1%. It is also not evidence of expansion: adjusted Industrial EBIT fell 25% and cash from operations fell $627 million YoY.
CNH’s engine is dealer sell-through → dealer inventory → factory production → fixed-cost absorption. Agriculture sales were flat at $3.277 billion, but margin compressed because South American volume, North American/EMEA mix, tariffs, labor and R&D overwhelmed pricing. Construction sales rose 12% because Q1-delayed units shipped, yet margin still fell to 1.7%; this is the classic timing-versus-structural test. Revenue recovered, but profitability did not, so delayed shipments are a timing positive while tariff and cost pressure are structural negatives.
Three causal KPIs are decisive. Agriculture industry demand fell 16–17% in key North American tractor categories, limiting dealer sell-through. Financial Services receivables over 30 days past due rose to 4.4% from 3.9% a year ago and 3.5% in Q1; this is a leading indicator of farmer stress and future risk cost. Industrial FCF was $150 million in Q2 but remained negative $439 million for H1, showing seasonality and working capital still dominate reported earnings. The compound negative is causal: weak farmer economics slows equipment demand, keeps inventory in the channel and worsens dealer/customer credit, which then constrains both manufacturing absorption and finance earnings.
The buried signal is that the upper-half guide is not an all-clear. Construction shipments delayed from Q1 lifted sales, but tariff pressure still reduced margin. A true trough requires sell-through and margin to improve together, not a shipment catch-up.
FY EPS moves from $0.35–0.45 to $0.41–0.46, a midpoint increase from $0.40 to $0.435. FCF midpoint rises from $250 million to $300 million. Driver algebra: retail demand × dealer inventory normalization → wholesale shipments; price/mix minus tariffs/labor/R&D → Industrial EBIT; finance portfolio yield minus funding and credit costs → Financial Services income; working capital converts EBIT to FCF. FY1 should rise 8.8% at the midpoint versus prior guide. For FY2, a 200 bps recovery in Agriculture margin on roughly $13 billion annualized sales could add about $260 million EBIT, but a further 100 bps credit deterioration and persistent tariffs can absorb a meaningful portion.
At $10.25, midpoint guided EPS implies 23.6x and midpoint FCF only a 2.4% yield on market cap. At $8.50, P/E is 19.5x; still not cheap, but a better entry into the cyclical option. Without a validated FY2 margin recovery, the release does not support a higher price target.
| Claim | Evidence | Verdict | Next proof |
|---|---|---|---|
| Agriculture is at trough | guide floor raised; dealer inventory normalizing | strengthened, not confirmed | Q3 sell-through |
| Construction recovery has operating leverage | sales +12%, margin -280 bps | weakened | Q3 margin |
| Farmer credit remains contained | past-due ratio 4.4% vs 3.5% Q1 | weakened | delinquency/loss data |
| Tariffs can be offset | guide raised despite tariffs | strengthened, details pending | tariff dollars |
| Pillar | Status |
|---|---|
| Demand / volume | UNRESOLVED |
| Pricing / mix | REINFORCED |
| Margin architecture | WEAKENED |
| Competition / dealer position | UNCHANGED |
| Balance sheet / cash | UNRESOLVED |
| Management credibility | IMPROVED |
| Catalyst timing | IMPROVED |
Entering the print, CNH was a trough-year execution story. After release, management proved enough cost and pricing control to raise the lower bounds, but credit and margin data prevented an inflection call. After call and settled reaction are PENDING — CALL. Business delta: modestly better trough floor. Estimate delta: FY1 up high single digits; FY2 unresolved. Stock delta: too much recovery is priced for current FCF.
Three call questions: How much dealer inventory fell by region and when does retail sell-through exceed wholesale? What tariff dollars are embedded in Q2 and FY guide? Why did 30-day past dues rise 90 bps from Q1, and what is the loss-content sensitivity?
Decision card: WAIT; no size. Confirm with Ag margin at least 5.5%, Construction margin above 2.3%, and past-dues back below 4.0%. Falsify if FCF is below $200 million or past-dues exceed 5%. Entry: $8.50 or below. Next proof: 09:00 call and Q3. PM line: the guide floor rose, but the cash/credit floor is not proven.
PM decision line — WAIT, moderate confidence, PROVISIONAL — RELEASE ONLY. Nasdaq’s EPS snapshot was $1.70; Krystal reported $1.79 and VYJUVEK revenue of $119.2 million, +24% YoY. The commercial engine remains exceptional, but sequential product growth slowed to 2.4% and KB408/KB707 timing moved into 2027/1H27. At $341.12, the enterprise value is roughly 19x annualized product revenue; wait for $300 or successful IOLITE data.
| Metric | Prior / Street | Q2 actual | Rate of change | Classification |
|---|---|---|---|---|
| Diluted EPS | Nasdaq $1.70 | $1.79 | +$0.09; +39% YoY; down from $1.83 Q1 | POSITIVE, not thesis-defining |
| VYJUVEK revenue | Q1 $116.4M | $119.2M | +2.4% QoQ, +24% YoY vs +32% YoY in Q1 | STRUCTURAL POSITIVE, DECELERATING |
| Gross margin | Q1 95% | 95% | stable | STRUCTURAL POSITIVE |
| Reimbursement approvals | >695 Q1 | >730 | +35 QoQ | STRUCTURAL POSITIVE |
| Unique prescribers | >570 Q1 | >640 | +70 QoQ | STRUCTURAL POSITIVE |
| Pipeline timing | KB408 2026; KB707 update 2026 | KB408 interim 2027; KB707 update 1H27 | two delays | STRUCTURAL NEGATIVE |
EPS quality is acceptable: operating income was $58.4 million and interest income only $7.7 million, so below-the-line income contributed about 12% of pre-tax income, below the 30% low-quality threshold. There was no material buyback or tax artifact creating the beat. Still, EPS is subordinate to product revenue and clinical probability.
VYJUVEK is a recurring topical gene therapy for a chronic wound condition. Revenue equals eligible patients × reimbursement approval × prescriber activation × treatment persistence × realized price. The 95% gross margin converts incremental revenue almost directly into operating resources. Approvals rose about 5% sequentially and prescribers about 12%, but revenue only 2.4%; that gap may reflect patient onboarding, wound-treatment cadence or international pricing. It is the key question for the call.
The company is using one commercial asset to fund several platform shots. Cash and investments reached $1.1 billion, while quarterly R&D remained only $14.5 million. That gives Krystal unusual financing independence for biotech. The compound positive is causal: high-margin VYJUVEK generates cash, which funds registrational programs without dilutive capital, preserving per-share upside. The compound negative is also causal: valuation capitalizes multiple pipeline options, so timeline slips reduce present value even when the commercial product performs.
The buried signal is mixed. IOLITE remains on track for 4Q 2026 and EMERALD-1 enrollment by year-end, preserving the nearest major option. But KB408 interim results moved from 2026 to 2027, and KB707’s update moved into 1H 2027. The release therefore narrows near-term value creation around IOLITE; this increases the binary importance of one readout.
No product-revenue guide or dated revenue consensus was publicly verifiable, so the model uses transparent sensitivity. Annualizing Q2 gives $477 million product revenue. At 95% gross margin, each additional $50 million revenue adds about $47.5 million gross profit before commercial/R&D spend. A FY1 revenue range of $470–500 million and operating expense near the company’s $175–195 million non-GAAP R&D+SG&A guide supports continued profitability. FY2 depends on international launches and persistence: 15–25% product growth would add $70–120 million revenue, while pipeline value changes discretely with IOLITE/EMERALD evidence.
At $341.12, market cap is roughly $10.1 billion and net cash about $1.1 billion, so EV is approximately $9.0 billion, or 18.9x annualized Q2 revenue. At $300, EV falls near $7.8 billion, or 16.4x. That is still premium, but it improves the asymmetry before IOLITE.
| Claim | Evidence | Verdict | Next proof |
|---|---|---|---|
| VYJUVEK has durable recurring demand | revenue +24%, approvals/prescribers up | strengthened | Q3 revenue |
| International launch adds next leg | Germany/France talks continue; Italy/Spain expected by year-end | unresolved | reimbursement |
| Platform reduces single-product risk quickly | two program updates shifted into 2027 | weakened | clinical calendar |
| Balance sheet removes financing risk | $1.1B cash/investments | strengthened | spend cadence |
| Pillar | Status |
|---|---|
| Demand / volume | REINFORCED |
| Pricing / mix | UNRESOLVED |
| Margin architecture | REINFORCED |
| Competitive position | REINFORCED |
| Balance sheet | IMPROVED |
| Management credibility | WEAKENED |
| Catalyst timing | WEAKENED |
Entering the print, the story was VYJUVEK durability plus a broad 2H clinical catalyst stack. After release, VYJUVEK remained sound but the catalyst stack concentrated around IOLITE. After call and market reaction are PENDING — CALL. Business delta: commercial franchise intact. Estimate delta: modestly positive EPS, unchanged product model absent guidance. Stock delta: the premium makes timeline slips economically material.
Three call questions: Why did revenue grow only 2.4% sequentially despite faster prescriber growth? What operational issue moved KB408 and KB707 disclosures into 2027? What probability and commercial assumptions should investors use for Italy/Spain launches before year-end?
Decision card: WAIT, 0% size. Confirm with Q3 VYJUVEK revenue above $125 million and successful IOLITE 4Q data. Falsify if product revenue falls below $115 million or IOLITE slips beyond 4Q. Entry: $300 or below before data, or re-underwrite after positive IOLITE. PM line: excellent commercial economics, but the release reduced near-term pipeline breadth.
Decision — WAIT at $47 or lower; PROVISIONAL — RELEASE ONLY. CNA delivered $1.19 core EPS versus Nasdaq’s $1.04 snapshot, but core income fell 3% YoY. Higher investment income and lower investment losses supported earnings while the underlying combined ratio worsened to 94.2% from 91.7%. This is an earnings beat with weaker underwriting quality.
| KPI | Q2 2026 | Comparison | Mechanism / classification |
|---|---|---|---|
| Core EPS | $1.19 | $1.23 YoY; $1.04 Nasdaq | beat Street, declined YoY |
| Underlying combined ratio | 94.2% | 91.7% YoY; loss ratio flat sequentially | STRUCTURAL NEGATIVE |
| Net written premiums | +4% | new business +11%, retention 83% | volume positive |
| Renewal premium change / rate | +2% / flat | casualty offsets property/WC/international declines | PRICING NEGATIVE |
| Net investment income | $701M | +$39M YoY | STRUCTURAL POSITIVE from reinvestment |
| Catastrophe losses | $60M / 2.3 pts | $62M / 2.4 pts YoY | immaterial variance |
The causal KPIs are renewal rate, underlying loss ratio and expense ratio. Flat rate against social inflation means current pricing may not cover future casualty loss trends; the loss ratio already increased 260 bps YoY. New business at a record $718 million can grow premiums but becomes value-destructive if selected at inadequate rate. Investment income provides a real offset because fixed-income reinvestment occurs at higher yields, but it should not be mistaken for underwriting improvement. The compound negative is new-business growth plus softer pricing plus a higher underlying loss ratio. The buried signal is that the loss ratio held at 64.1% sequentially after conservative Q1 loss picks; deterioration did not accelerate in Q2, so the issue is level, not another sequential break.
EPS quality is mixed. Core EPS excludes investment gains/losses, while Corporate & Other includes a $77 million after-tax legacy mass-tort charge. The core beat is supported by investment income, not tax or share count, but limited-partnership returns can be volatile. No full public Q&A was offered; the issuer posted prepared remarks, so sentiment is NO_PUBLIC_CALL and no score is assigned.
FY1 algebra is earned premiums × (1 − combined ratio) + investment income − legacy/corporate losses. A 100 bps change in combined ratio on roughly $10.5 billion annualized earned premium is about $105 million pretax, or roughly $0.30 per share after tax. FY2 improves only if casualty price again exceeds loss trend. At $52.47, the stock is 1.14x $45.83 ex-AOCI book value and about 11x annualized Q2 core EPS. At $47, it is near 1.03x ex-AOCI book, providing better protection against reserve volatility.
Debate: the bull claim that high reinvestment yields protect earnings is strengthened; the bear claim that commercial pricing is softening is strengthened; the claim that Q1 reserve conservatism created a floor is unresolved. Thesis pillars: demand REINFORCED; pricing WEAKENED; margins WEAKENED; competition UNRESOLVED; balance sheet REINFORCED; credibility UNRESOLVED without Q&A; catalyst timing UNCHANGED. Business delta is weaker underwriting with stable sequential loss picks. Estimate delta is a near-term EPS beat but lower-quality mix. Stock delta is neutral at the preprint price.
Three questions for management’s next interactive forum: What casualty loss trend is embedded in flat rate? How much of record new business meets target combined-ratio thresholds? What reserve sensitivity remains in legacy mass tort after the $77 million charge?
Decision card: WAIT; confirm when renewal rate exceeds 3% and underlying combined ratio falls below 93.5%. Falsify if underlying combined ratio exceeds 95% or adverse development rises. Entry $47. Next proof Q3 2026. PM line: investment income beat; underwriting did not.
Decision — WAIT at $19.50 or below; PROVISIONAL — RELEASE ONLY / NO PUBLIC INVESTOR MEETING. MUFG earned ¥809.4 billion attributable profit, +48% YoY, equal to 30% of its unchanged ¥2.7 trillion FY target in one quarter. The Japan-rate thesis is operating: net interest income rose 28% and gross profit 28%. Credit costs also increased, and the ADR already embeds a premium to book.
| KPI | Q1 FY2027 | YoY / target | Classification |
|---|---|---|---|
| Attributable profit | ¥809.4B | +48.2%; 30.0% of FY target | STRUCTURAL POSITIVE |
| Net interest income | ¥882.4B | +¥191.6B / +27.7% | STRUCTURAL POSITIVE |
| Net fees/commissions | ¥558.2B | +20.9% | STRUCTURAL POSITIVE |
| Net trading profit | ¥132.7B | +210% | POSITIVE, less durable |
| Total credit costs | ¥72.1B | ¥46.9B prior year | STRUCTURAL NEGATIVE |
| Shareholders’ equity | ¥22.7T | +1.9% since March | POSITIVE |
The bank engine is loan/deposit spread × balance-sheet volume plus fees and markets, less expenses and credit costs. Higher yen rates reprice assets faster than deposits, lifting NII; this is the core causal KPI. Fee growth broadens the earnings source. Credit costs are the counterweight: the bank increased future-loss qualitative adjustments to ¥28.4 billion from ¥24.4 billion at March, acknowledging geopolitical and commodity uncertainty. The compound positive is NII plus fees plus trading; the compound negative is higher expenses and credit costs. The buried signal is pro-rata target coverage: even if the remaining quarters average only about ¥630 billion, MUFG reaches ¥2.7 trillion. That creates target upside, but management did not raise the goal.
Nasdaq’s $0.34 EPS snapshot cannot be cleanly reconciled to ¥71.77 basic EPS because ADR/share conversion, FX timestamp and Japanese-GAAP presentation were not specified; it is marked not verifiable, not treated as a beat. EPS quality is good at the operating level because NII and fees explain most growth, although trading profit is less repeatable.
FY1 algebra is NII + fees + trading − G&A − credit costs − tax. Annualizing the quarter overstates markets income, so retain the ¥2.7 trillion target. With roughly 11.3 billion shares, that is about ¥239 per share. The $22.45 ADR translated near the July 31 yen rate implies a mid-teens target P/E and roughly 1.7x June shareholders’ equity; exact ADR FX sensitivity is material. A 10% NII upside with a 50% credit-cost increase still likely leaves profit above target, but a BOJ reversal or deposit-beta jump would compress the spread.
Debate: the bull claim that Japanese normalization creates durable NII is strengthened; the bear claim that credit costs will rise is strengthened; capital return remains unresolved because the ¥96 dividend was unchanged. Thesis pillars: demand/loan volume UNRESOLVED; pricing/spread IMPROVED; margins IMPROVED; competition UNCHANGED; capital REINFORCED; credibility UNRESOLVED because target was not raised; catalyst timing IMPROVED. Business delta is a higher earnings floor from rates. Estimate delta is positive versus pro-rata target. Stock delta is less attractive because valuation recognizes normalization.
Three questions for the next investor disclosure: What deposit beta and BOJ path sit behind the target? Which borrower/geography drove higher credit costs? What threshold would trigger a target or buyback increase?
Decision card: WAIT; confirm if H1 profit exceeds ¥1.4 trillion and NII stays above ¥850 billion quarterly. Falsify if credit costs exceed ¥150 billion quarterly or NII falls below ¥750 billion. Entry $19.50. PM line: the earnings engine accelerated, but target and capital return did not.
Loews reported Q2 net income of $444 million, or $2.16 per share, versus $391 million/$1.87 a year ago. CNA contributed $294 million; Boardwalk $100 million; Hotels $48 million; Corporate $2 million. Ex-AOCI book value rose to $99.27 from $95.89 at year-end, and Loews repurchased 1.4 million shares for $146 million, about $104 per share, below the July 31 close of $116.01.
The facts support positive NAV compounding: Boardwalk benefited from higher transport contracting rates and projects, hotels from ADR/occupied-room growth, and repurchases reduced shares 0.8% during the quarter. Full analysis is not complete because the AM evidence had no dated consensus, no segment valuation hurdle and no interactive Q&A; CNA’s underwriting economics are analyzed separately above. The decisive missing datum is a target sum-of-the-parts discount using current CNA market value, Boardwalk EBITDA multiple, hotel value and parent net cash. No fresh BUY/SELL is issued. Catch-up deadline: 2026-08-04.
No unresolved U.S.-listed >$2 billion prior-evening AMC company was verified for Sunday, 2026-08-02. WHR was rescheduled to release after the 2026-08-03 close and belongs to the PM workflow. ON, TKO, FMS and other later 2026-08-03 releases are also excluded from AM based on filing/release time.
| Ticker | Required evidence | Three unresolved issues | Original catch-up deadline |
|---|---|---|---|
| [[MAR]] | complete call + prior transcript | card recurrence; Middle East bookings; interest/buybacks | 2026-08-03 20:00 ET |
| [[TSN]] | complete call + prior transcript | Beef assumptions; Chicken margin; Prepared Foods | 2026-08-03 20:00 ET |
| [[CNH]] | complete call + prior transcript | dealer inventory; tariff dollars; delinquencies | 2026-08-03 20:00 ET |
| [[KRYS]] | complete call + prior transcript | VYJUVEK cadence; delays; Europe launches | 2026-08-03 20:00 ET |
| [[CNA]] | no public Q&A; future interactive evidence | loss trend; new-business quality; reserves | next investor forum / Q3 |
| [[MUFG]] | no investor meeting listed | deposit beta; credit costs; capital return | next presentation / H1 |
| [[L]] | SOTP inputs and remarks | CNA look-through; Boardwalk value; buyback discount | 2026-08-04 |
| Ticker | Tier | Status | Analytical words | Causal KPIs | Q&A | Debate claims | Prior-call deltas | Omissions | FY1/FY2 bridge | Transcript provenance | Sentiment | Tone delta | Answer quality | Pressure delta | Tracker read-back | Failed/deferred gates | |---|---:|---|---:|---:|---:|---:|---:|---|---|---|---|---|---|---|---| | MAR | 1 | PROVISIONAL | 1,017 | 4 | 0 | 3 | 0 | 1 | sensitivity complete | call incomplete at 08:00 | PENDING_TRANSCRIPT | N/A | N/A | N/A | yes | call-only gates blocked | | TSN | 1 | PROVISIONAL | 973 | 5 | 0 | 4 | 0 | 1 | sensitivity complete | call incomplete at 08:00 | PENDING_TRANSCRIPT | N/A | N/A | N/A | yes | call-only gates blocked | | CNH | 1 | PROVISIONAL | 921 | 5 | 0 | 4 | 0 | 1 | sensitivity complete | 09:00 call pending | PENDING_TRANSCRIPT | N/A | N/A | N/A | yes | call-only gates blocked | | KRYS | 1 | PROVISIONAL | 822 | 5 | 0 | 4 | 0 | 1 | sensitivity complete | 08:30 call pending | PENDING_TRANSCRIPT | N/A | N/A | N/A | yes | call-only gates blocked | | CNA | 2 | PROVISIONAL | 574 | 5 | 0 | 3 | 0 | 1 | sensitivity complete | remarks; no public Q&A | NO_PUBLIC_CALL | N/A | N/A | N/A | yes | final scoring N/A | | MUFG | 2 | PROVISIONAL | 571 | 5 | 0 | 3 | 0 | 1 | sensitivity complete | no meeting listed | NO_PUBLIC_CALL | N/A | N/A | N/A | yes | ADR consensus blocked | | L | 3 | DEFERRED | 164 | 2 | 0 | 1 | 0 | 1 | deferred | prepared remarks only | DEFERRED | N/A | N/A | N/A | yes | SOTP/consensus deferred |